

UNICEF programmatic support to PCV and RVV introduction and supply outlook

Abu Obeida Eltayeb, UNICEF Somalia
Dr Oya Zeren Afşar, UNICEF NYHQ


Introducing PCV and Rotavirus Vaccine
13-15 September 2023, N'Djamena, Chad



Global Strategies and Partnerships

01

Global Action Plan for Pneumonia and Diarrhoea



02

Immunization Agenda 2030




03

UNICEF Immunization Roadmap to 2030



How does UNICEF support countries to introduce PCV and Rotavirus vaccines (1)

- **Advocacy to the governments and support to resource mobilization,**
- **Positioning PCV and RVV introduction as part of other pneumonia and diarrhea control strategies,**
- **Development of new vaccine introduction plans and Gavi applications,**
- **Utilizing immunization coverage & equity assessments to ensure the new vaccines reach zero-dose communities,**
- **Capacity building of health staff, Community Health Workers,**
- **Contributing to readiness assessments, field monitoring, and post-introduction evaluations.**



How does UNICEF support countries to introduce PCV and Rotavirus vaccines (2)

- Improving vaccine demand and uptake through community mobilization, innovative partnerships and digital tools – social listening,
- Strengthening immunization supply chain – cold chain equipment, solarization of health facilities, monitoring stock-outs,
- Providing vaccines and other immunization supplies,
- Sharing lessons learned and case studies from other countries, documenting and disseminating results to facilitate cross-country learning.

unicef 
for every child



Pneumococcal Conjugate Vaccine (PCV) Market Update

Useful links:

- [PCV supply and demand update 2020](#)
- [PCV unit price data](#)

WHO Prequalified PCV Vaccines




Manufacturer	Vaccine Type	Doses / Course	WHO PQ	Presentation	Form.	Shelf life	VVM	Cold Chain Vol / Dose	Storage
GSK (Belgium)	PCV10	3	2009	1-dose vial	Liquid	48 months	30	11.50 cm ³	2-8°C
		3	2010	2-dose vial	Liquid	48 months	30	4.80 cm ³	2-8°C
		3	2017	4-dose vial	Liquid	36 months	30	2.40 cm ³	2-8°C
Pfizer (USA)	PCV13	3	2010	1-dose vial	Liquid	36 months	30	12.00 cm ³	2-8°C
		3	2016	4-dose vial	Liquid	36 months	30	3.50 cm ³	2-8°C
SII (India)	PCV10	3	2019	1-dose vial	Liquid	36 months	30	14.06 cm ³	2-8°C
	PCV10	3	2019	5-dose vial	Liquid	36 months	30	3.51 cm ³	2-8°C

- PCV10 vaccines from GSK and SII have a different serotype
 - GSK PCV10: type 4
 - SII PCV10: type 19A
- GSK PCV10 2-dose presentation was phased out in 2019.

Historical Procurement, Supply Outlook & Pricing



UNICEF Annual Procurement Volume



Global supply is sufficient to meet demand. Advanced planning is critical if procuring through UNICEF.

WAP for Gavi-eligible countries has declined over time with new products entering the market.

Pricing for Gavi-eligible countries per dose through UNICEF:

- PCV10, 4-dose vial (GSK): \$3.05
- PCV10, 1-dose vial (SII): \$2.90
- PCV10, 5-dose vial (SII): \$1.50
- PCV13, 1-dose vial (Pfizer): \$3.30
- PCV13, 4-dose vial (Pfizer): \$2.75

PCV Vaccine Lead Time



PCV has sufficient supply but little room for sudden and substantial quantity changes due to production lead time. **Long term reliable forecast and timely financing are vital.** Procurement of large additional quantities has to be communicated well in advance (depending on the product, from 6 months to 2 years)

UNICEF Annual Forecast exercise has been already initiated and countries' forecasts are **expected by 18 September**

Countries' plans to introduce PCV in 2024/2025 should be reflected in their vaccine forecasts and shared with UNICEF as soon as possible

For **properly forecasted and planned deliveries**, vaccine **lead time is around 6-8 weeks** from the time funding is made available for UNICEF

Rotavirus Vaccine (RVV) Market Update

Useful links:

- [RVV supply and demand update 2022](#)
- [RVV unit price data](#)

WHO Prequalified RV Vaccines




Manufacturer	Doses/ Course	WHO PQ	Presentation	Formulation	Shelf life	VVM	Cold Chain Vol / Course	Storage
Bharat Biotech (India)	3	2018	5-dose vial	Liquid-frozen	24 months	2	12.6 cm ³	-20°C
	3	2018	10-dose vial	Liquid-frozen	24 months	2	9.6 cm ³	-20°C
	3	2021	5-dose vial	Liquid	24 months	7	12.6 cm ³	2-8°C
	3	2021	1-dose vial	Liquid	60 months	7	48.0 cm ³	2-8°C
GlaxoSmithKline (Belgium)	2	2009	1-dose tube	Liquid	24 months	7	34.2 cm ³	2-8°C
	2	2009	1-dose applicator	Liquid	24 months	n/a	170.6 cm ³	2-8°C
	2	2019	5 x 1-dose tubes*	Liquid	24 months	7	23.6cm ³	2-8°C
Merck, Sharpe & Dohme (USA)	3	2008	1-dose tube	Liquid	24 months	n/a	138.9 cm ³	2-8°C
Serum Institute of India	3	2018	1-dose vial	Lyophilised	30-months	30	52.71 cm ³	2-8°C
	3	2018	2-dose vial	Lyophilised	30-months	30	31.62 cm ³	2-8°C
	3	2021	1-dose vial	Liquid	24-months	7	60.2 cm ³	2-8°C
	3	2021	2-dose vial	Liquid	24-months	7	42.90cm ³	2-8°C
	3	2000	1-dose vial	Lyophilised	30 months	250+	52.71 cm ³	<25 °C
	3	2000	2-dose vial	Lyophilised	30 months	250+	31.62 cm ³	<25 °C

UNICEF procures 5 presentations out of 14 WHO prequalified Rotavirus Vaccines

Merck existed the Gavi market in 2020 and there are three manufacturers for the Gavi market.

Note *: GSK's blow-fill seal presentation

Historical Procurement, Supply Outlook & Pricing



The supply situation is expected to stabilize following multiple supply disruptions in 2021 and 2022 due to reduced production efficiency and technical difficulties.

WAP for Gavi-eligible countries has declined over time with new products entering the market.

Pricing for Gavi-eligible countries per dose through UNICEF:

- RV1, 5-dose vial, frozen (BBIL): \$0.85
- RV1, 10-dose vial, frozen (BBIL): \$0.60
- RV1, 1-dose tube, liquid (GSK): €2.05
- RV5, 2-dose vial, lyophilized (SII): \$0.95
- RV5, 2-dose vial, liquid (SII): \$0.80



unicef 
for every child

Thank you.

